111.64
price up icon0.20%   0.2401
 
loading
Schlusskurs vom Vortag:
$111.40
Offen:
$111.64
24-Stunden-Volumen:
419.13K
Relative Volume:
0.21
Marktkapitalisierung:
$220.02B
Einnahmen:
$51.72B
Nettoeinkommen (Verlust:
$11.94B
KGV:
18.99
EPS:
5.88
Netto-Cashflow:
$13.81B
1W Leistung:
-0.45%
1M Leistung:
+2.36%
6M Leistung:
-3.45%
1J Leistung:
+15.40%
1-Tages-Spanne:
Value
$111.26
$111.87
1-Wochen-Bereich:
Value
$108.65
$112.23
52-Wochen-Spanne:
Value
$92.35
$120.92

Novartis Ag Adr Stock (NVS) Company Profile

Name
Firmenname
Novartis Ag Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
75,883
Name
Twitter
@novartis
Name
Nächster Verdiensttermin
2025-01-31
Name
Neueste SEC-Einreichungen
Name
NVS's Discussions on Twitter

Vergleichen Sie NVS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
111.69 220.02B 51.72B 11.94B 13.81B 5.88
Drug Manufacturers - General icon
LLY
Lilly Eli Co
823.77 741.33B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
ABBV
Abbvie Inc
202.78 359.10B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.35 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
70.04 311.44B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
MRK
Merck Co Inc
89.62 223.02B 64.17B 17.12B 18.10B 6.73

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-13 Herabstufung UBS Buy → Neutral
2025-02-12 Eingeleitet Morgan Stanley Underweight
2025-02-04 Hochstufung Deutsche Bank Hold → Buy
2024-12-04 Herabstufung HSBC Securities Hold → Reduce
2024-09-11 Herabstufung BofA Securities Buy → Neutral
2024-09-05 Herabstufung Goldman Buy → Neutral
2024-09-03 Herabstufung Jefferies Buy → Hold
2024-07-19 Herabstufung Deutsche Bank Buy → Hold
2024-05-30 Eingeleitet Goldman Buy
2024-02-23 Eingeleitet BMO Capital Markets Market Perform
2024-01-23 Eingeleitet Morgan Stanley Equal-Weight
2024-01-16 Fortgesetzt UBS Buy
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-09-25 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-26 Hochstufung Deutsche Bank Hold → Buy
2023-03-27 Hochstufung Deutsche Bank Sell → Hold
2023-01-26 Herabstufung Citigroup Buy → Neutral
2022-12-05 Hochstufung Stifel Hold → Buy
2022-09-15 Herabstufung Credit Suisse Neutral → Underperform
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-05-09 Herabstufung Wolfe Research Outperform → Peer Perform
2022-01-10 Fortgesetzt Citigroup Buy
2021-12-14 Herabstufung Redburn Buy → Neutral
2021-12-06 Herabstufung Exane BNP Paribas Outperform → Neutral
2021-12-03 Herabstufung Bryan Garnier Buy → Neutral
2021-09-20 Herabstufung Deutsche Bank Hold → Sell
2021-03-22 Eingeleitet Bernstein Mkt Perform
2021-03-10 Herabstufung Argus Buy → Hold
2021-02-01 Herabstufung Cowen Outperform → Market Perform
2021-01-15 Eingeleitet Deutsche Bank Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-09-10 Hochstufung UBS Neutral → Buy
2020-09-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-15 Hochstufung Citigroup Neutral → Buy
2020-03-10 Hochstufung Morgan Stanley Underweight → Equal-Weight
2020-02-25 Herabstufung Guggenheim Buy → Neutral
2019-04-25 Hochstufung Guggenheim Neutral → Buy
2019-04-25 Hochstufung Liberum Hold → Buy
2019-04-10 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-01-02 Herabstufung JP Morgan Neutral → Underweight
2018-12-11 Fortgesetzt Jefferies Buy
2018-10-09 Eingeleitet Guggenheim Neutral
2018-09-10 Hochstufung BofA/Merrill Underperform → Buy
2018-05-29 Herabstufung HSBC Securities Buy → Hold
2018-05-25 Hochstufung Credit Suisse Underperform → Neutral
2018-01-25 Bestätigt Leerink Partners Outperform
2017-12-06 Herabstufung BofA/Merrill Neutral → Underperform
2017-07-26 Hochstufung Morgan Stanley Underweight → Overweight
2017-07-05 Herabstufung Credit Suisse Neutral → Underperform
2017-03-09 Eingeleitet Liberum Buy
Alle ansehen

Novartis Ag Adr Aktie (NVS) Neueste Nachrichten

pulisher
Mar 27, 2025

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar

Mar 27, 2025
pulisher
Mar 27, 2025

Why Pfizer Is My Largest Healthcare Position - The Motley Fool

Mar 27, 2025
pulisher
Mar 25, 2025

5 Large Drug Stocks To Watch As Industry Recovers - Barchart

Mar 25, 2025
pulisher
Mar 21, 2025

FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart

Mar 21, 2025
pulisher
Mar 19, 2025

Novartis scraps use of diverse panels for hires in US - Reuters

Mar 19, 2025
pulisher
Mar 14, 2025

Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart

Mar 14, 2025
pulisher
Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 12, 2025

Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.

Mar 12, 2025
pulisher
Mar 07, 2025

Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart

Mar 07, 2025
pulisher
Mar 07, 2025

Giovanni Caforio, M.D. - Novartis

Mar 07, 2025
pulisher
Mar 05, 2025

Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily

Mar 05, 2025
pulisher
Mar 04, 2025

META_TITLE_QUOTE - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily

Mar 04, 2025
pulisher
Mar 03, 2025

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance

Mar 03, 2025
pulisher
Mar 03, 2025

Novartis Gets CHMP Opinion For Label Expansion Of Fabhalta - Barchart

Mar 03, 2025
pulisher
Feb 26, 2025

AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com

Feb 26, 2025
pulisher
Feb 25, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Feb 25, 2025
pulisher
Feb 21, 2025

NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com

Feb 21, 2025
pulisher
Feb 18, 2025

NVS Quantitative Stock Analysis - Nasdaq

Feb 18, 2025
pulisher
Feb 16, 2025

Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha

Feb 16, 2025
pulisher
Feb 13, 2025

Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Feb 13, 2025
pulisher
Feb 13, 2025

Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart

Feb 13, 2025
pulisher
Feb 11, 2025

Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors UK

Feb 11, 2025
pulisher
Feb 09, 2025

Novartis 2017 Financial Results - Novartis

Feb 09, 2025
pulisher
Feb 07, 2025

ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Feb 07, 2025
pulisher
Feb 06, 2025

Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News

Feb 06, 2025
pulisher
Feb 06, 2025

Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online

Feb 06, 2025
pulisher
Feb 03, 2025

HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily

Feb 03, 2025
pulisher
Feb 03, 2025

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise

Feb 03, 2025
pulisher
Feb 03, 2025

Novartis's SWOT analysis: pharma giant's stock navigates generic headwinds - Investing.com

Feb 03, 2025
pulisher
Feb 01, 2025

Novartis Earnings: Results In-Line; Growth Brands to Offset Entresto Loss of Exclusivity in 2025 - Morningstar

Feb 01, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q1 2021 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q2 2023 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

World Economic Forum Annual Meeting 2025 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Posts Q4 Earnings And Sales Beat, Shares Gain - Barchart

Jan 31, 2025
pulisher
Jan 31, 2025

LGBTQI+ inclusion - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis 2022 Financial Results - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis at ASH - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis 2021 Financial Results - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q1 2023 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis ADR earnings beat by $0.16, revenue topped estimates - Investing.com South Africa

Jan 31, 2025
pulisher
Jan 31, 2025

J.P. Morgan Healthcare Conference 2024 - Novartis

Jan 31, 2025

Finanzdaten der Novartis Ag Adr-Aktie (NVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general MRK
$89.28
price up icon 1.91%
$307.32
price up icon 0.41%
drug_manufacturers_general PFE
$25.00
price down icon 0.10%
$111.06
price up icon 1.73%
drug_manufacturers_general SNY
$55.91
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):